Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.

Chronic rejection is the major cause of long-term heart allograft failure, characterized by tissue infiltration by recipient T cells with indirect allospecificity. Phosphoinositol-3-kinase p110δ is a key mediator of T cell receptor signaling, regulating both T cell activation and migration of primed...

Full description

Saved in:
Bibliographic Details
Main Authors: Huijun Ying, Hongmei Fu, Marlene L Rose, Ann M McCormack, Padmini Sarathchandra, Klaus Okkenhaug, Federica M Marelli-Berg
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0032892&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849434468182392832
author Huijun Ying
Hongmei Fu
Marlene L Rose
Ann M McCormack
Padmini Sarathchandra
Klaus Okkenhaug
Federica M Marelli-Berg
author_facet Huijun Ying
Hongmei Fu
Marlene L Rose
Ann M McCormack
Padmini Sarathchandra
Klaus Okkenhaug
Federica M Marelli-Berg
author_sort Huijun Ying
collection DOAJ
description Chronic rejection is the major cause of long-term heart allograft failure, characterized by tissue infiltration by recipient T cells with indirect allospecificity. Phosphoinositol-3-kinase p110δ is a key mediator of T cell receptor signaling, regulating both T cell activation and migration of primed T cells to non-lymphoid antigen-rich tissue. We investigated the effect of genetic or pharmacologic inactivation of PI3K p110δ on the development of chronic allograft rejection in a murine model in which HY-mismatched male hearts were transplanted into female recipients. We show that suppression of p110δ activity significantly attenuates the development of chronic rejection of heart grafts in the absence of any additional immunosuppressive treatment by impairing the localization of antigen-specific T cells to the grafts, while not inducing specific T cell tolerance. p110δ pharmacologic inactivation is effective when initiated after transplantation. Targeting p110δ activity might be a viable strategy for the treatment of heart chronic rejection in humans.
format Article
id doaj-art-65dd6dbf09034d55ac309e0df66ebb50
institution Kabale University
issn 1932-6203
language English
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-65dd6dbf09034d55ac309e0df66ebb502025-08-20T03:26:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0173e3289210.1371/journal.pone.0032892Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.Huijun YingHongmei FuMarlene L RoseAnn M McCormackPadmini SarathchandraKlaus OkkenhaugFederica M Marelli-BergChronic rejection is the major cause of long-term heart allograft failure, characterized by tissue infiltration by recipient T cells with indirect allospecificity. Phosphoinositol-3-kinase p110δ is a key mediator of T cell receptor signaling, regulating both T cell activation and migration of primed T cells to non-lymphoid antigen-rich tissue. We investigated the effect of genetic or pharmacologic inactivation of PI3K p110δ on the development of chronic allograft rejection in a murine model in which HY-mismatched male hearts were transplanted into female recipients. We show that suppression of p110δ activity significantly attenuates the development of chronic rejection of heart grafts in the absence of any additional immunosuppressive treatment by impairing the localization of antigen-specific T cells to the grafts, while not inducing specific T cell tolerance. p110δ pharmacologic inactivation is effective when initiated after transplantation. Targeting p110δ activity might be a viable strategy for the treatment of heart chronic rejection in humans.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0032892&type=printable
spellingShingle Huijun Ying
Hongmei Fu
Marlene L Rose
Ann M McCormack
Padmini Sarathchandra
Klaus Okkenhaug
Federica M Marelli-Berg
Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
PLoS ONE
title Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
title_full Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
title_fullStr Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
title_full_unstemmed Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
title_short Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
title_sort genetic or pharmaceutical blockade of phosphoinositide 3 kinase p110δ prevents chronic rejection of heart allografts
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0032892&type=printable
work_keys_str_mv AT huijunying geneticorpharmaceuticalblockadeofphosphoinositide3kinasep110dpreventschronicrejectionofheartallografts
AT hongmeifu geneticorpharmaceuticalblockadeofphosphoinositide3kinasep110dpreventschronicrejectionofheartallografts
AT marlenelrose geneticorpharmaceuticalblockadeofphosphoinositide3kinasep110dpreventschronicrejectionofheartallografts
AT annmmccormack geneticorpharmaceuticalblockadeofphosphoinositide3kinasep110dpreventschronicrejectionofheartallografts
AT padminisarathchandra geneticorpharmaceuticalblockadeofphosphoinositide3kinasep110dpreventschronicrejectionofheartallografts
AT klausokkenhaug geneticorpharmaceuticalblockadeofphosphoinositide3kinasep110dpreventschronicrejectionofheartallografts
AT federicammarelliberg geneticorpharmaceuticalblockadeofphosphoinositide3kinasep110dpreventschronicrejectionofheartallografts